SOHO Italy 1st School of Multiple Myeloma

 

SOHO Italy 1st School of Multiple Myeloma
A

ASCT in MM in Novel Agents Era: Is Long-Term Disease Control and Survival Attainable in Relapsing/Progressing After Allo-SCT?

By SOHO Italy 1st School of Multiple Myeloma FEATURING Attilio Olivieri
By SOHO Italy 1st School of Multiple Myeloma FEATURING Attilio Olivieri
10 views
February 5, 2021
0 Comments
Login to view comments. Click here to Login

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay
Videos
20:07
SOHO Italy 1st School of Multiple Myeloma

Present Landscape of R/R MM: Post-Bortezomib, Post-Lenalidomide

Feat. C. Cerchione
09:45
SOHO Italy 1st School of Multiple Myeloma

Near-Future Therapy Landscape of R/R MM at Second or Subsequent Rela…

Feat. C. Cerchione
30:19
SOHO Italy 1st School of Multiple Myeloma

[PRIVATE] Present & Near Future of R/R MM: Post-Bortezomib, Post…

Feat. C. Cerchione
13:49
SOHO Italy 1st School of Multiple Myeloma

MM & Extracellular Vesicles: Do MICA+ EVs Impair NKG2D-Mediated …

Feat. E. Vulpis
27:26
SOHO Italy 1st School of Multiple Myeloma

Cell-Adhesion System Targeting in MM: How Does JAM-A Expression Corr…

Feat. A. Solimando
22:20
SOHO Italy 1st School of Multiple Myeloma

Single-Cell Characterization of the BM Immune Microenvironment in MM…

Feat. C. Botta
23:39
SOHO Italy 1st School of Multiple Myeloma

ASCT in MM in Novel Agents Era: Is Long-Term Disease Control and Sur…

Feat. A. Olivieri
16:03
SOHO Italy 1st School of Multiple Myeloma

Primary Plasma Cell Leukemia Peru Experience: How Common Is PCL in M…

Feat. J. Vasquez
19:12
SOHO Italy 1st School of Multiple Myeloma

1st/2nd Relapse in MM: Predictive Factors, EMD, Role of sFLC in MGUS…

Feat. U. Markovic
16:38
SOHO Italy 1st School of Multiple Myeloma

Extracellular Vesicles in Myeloma: What Is Their Role in MGUS-to-MM …

Feat. A. Reale
13:44
SOHO Italy 1st School of Multiple Myeloma

MRD Assessment Within the Bone Marrow of MM: Immunoglobulin Genes as…

Feat. C. Terragna
22:16
SOHO Italy 1st School of Multiple Myeloma

Molecular Pathogenesis of MM: MGUS and SMM, Genomic Complexity of th…

Feat. N. Bolli
18:23
SOHO Italy 1st School of Multiple Myeloma

Bone Marrow Fibroblasts in MM Progression and Tumor Cells Reprogramm…

Feat. I. Saltarella
20:55
SOHO Italy 1st School of Multiple Myeloma

The Myeloma-Specific Tumor Suppressor FAM46C: How Does It Work &…

Feat. E. Milan
08:20
SOHO Italy 1st School of Multiple Myeloma

1L LenDex Combo in Frail MM Patients: How Effective Is It? Is There …

Feat. C. Bellofiore
13:41
SOHO Italy 1st School of Multiple Myeloma

NGS in ALL: Is INO Effective in MRD+ Patients Before HSCT? How Valua…

Feat. G. Martinelli
16:57
SOHO Italy 1st School of Multiple Myeloma

Anti-CD38 in MM Daily Practice: How Can We Potentiate the Action of …

Feat. C. Cerchione
26:05
SOHO Italy 1st School of Multiple Myeloma

Introducing Anti-CD38 in Daily Practice of MM: Updates on the GRIFFI…

Feat. C. Cerchione
19:13
SOHO Italy 1st School of Multiple Myeloma

Daratumumab in MM Daily Practice: Is It Becoming the New Backbone?

Feat. C. Cerchione
10:00
SOHO Italy 1st School of Multiple Myeloma

Bone Marrow CD8+ Tissue-Resident Memory T-Cells in MM: Can the Incre…

Feat. M. Carlisi
13:19
SOHO Italy 1st School of Multiple Myeloma

European Experience in MM: What Are the Potential 1L Options for Tra…

Feat. M. Mateos
10:48
SOHO Italy 1st School of Multiple Myeloma

Exploring Microenvironment of Multiple Myeloma: How Important Is It …

Feat. A. Romano
09:25
SOHO Italy 1st School of Multiple Myeloma

2021 Update Combination Therapies in R/R MM: Which Options Are the M…

Feat. F. Fazio
15:22
SOHO Italy 1st School of Multiple Myeloma

Dissecting Daratumumab Mechanisms of Resistance in MM: Identificatio…

Feat. M. Claudio Da Via
09:34
SOHO Italy 1st School of Multiple Myeloma

Comparison of Different Imaging Techniques in MM: Whole-Body Compute…

Feat. S. Grammatico
10:25
SOHO Italy 1st School of Multiple Myeloma

Combination Therapy in MM: Does Doxorubicin & ENPP1 Inhibitor Co…

Feat. L. Cuollo
11:33
SOHO Italy 1st School of Multiple Myeloma

Allograft in MM: Is There a Role for AlloHSCT & Will Newer Drug …

Feat. F. Vozella
14:02
SOHO Italy 1st School of Multiple Myeloma

2021 Update on R/R MM: Does the Addition of BCNU to Melphalan Improv…

Feat. J. Thomas